PRIA Logo™
119-hr-7694119th CongressWALLET

Gwenn’s Law

Sponsored By: Representative Gottheimer, Josh [D-NJ-5]

Introduced

Summary

This bill would aim to _increase women’s participation in NIH-supported clinical trials_ and spur development of treatments for rare diseases that disproportionately affect women. It directs targeted outreach, two focused awareness campaigns, and a new interagency task force to coordinate research and measure progress.

Show full summary
  • Would boost enrollment and engagement of women in NIH-conducted or NIH-supported clinical trials and in HHS programs for bleeding and clotting disorders, with priority on rare diseases that affect women.
  • Would fund two separate public awareness campaigns. Each campaign is authorized $10 million per year for fiscal years 2027–2031 to support outreach at hospitals, clinics, physicians’ offices, and other sites.
  • Would create a permanent Interagency Task Force on Advancing Treatments for Rare Diseases made up of federal health leaders and appointed public and advocacy representatives to assess programs, coordinate incentives for research, and identify measurable outcomes. The Task Force would be set up within 90 days and HHS would produce an action plan within 180 days for public posting and submission to Congress.

*Would authorize $10 million per year for each awareness campaign for 2027–2031, totaling $20 million per year during that period and thus increasing federal spending in those years.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

More outreach for women's bleeding disorders

If enacted, the Secretary of HHS would run a public awareness campaign to increase women’s participation in HHS research, surveillance, and prevention programs for bleeding and clotting disorders, including hemophilia. The campaign would focus on recruiting and engaging women in those HHS programs. Congress would be authorized to appropriate $10 million for each fiscal year 2027 through 2031 to carry out this campaign.

More outreach to enroll women in trials

If enacted, HHS, through the NIH Director, would run a public awareness campaign to increase women’s participation in NIH-conducted or NIH-supported clinical trials. The campaign would target hospitals, doctors' offices, health centers, clinics, and other locations the Secretary finds appropriate. It would prioritize trials of products to prevent, diagnose, or treat rare diseases and conditions. Congress would be authorized to appropriate $10 million for each fiscal year 2027 through 2031 to carry out this campaign.

Task force for rare disease treatments

If enacted, the bill would add a permanent Interagency Task Force on Advancing Treatments for Rare Diseases to the Public Health Service Act. HHS would have 90 days after enactment to establish the task force. Members would include senior HHS officials and eight Secretary-appointed members from industry, research institutions, and rare disease advocacy groups. The task force would assess federal rare disease activities, review program funding, identify measurable outcomes, and coordinate efforts to incentivize research and product development, especially for diseases that disproportionately affect women.

Sponsors & CoSponsors

Sponsor

Gottheimer, Josh [D-NJ-5]

NJ • D

Cosponsors

  • Rep. Pettersen, Brittany [D-CO-7]

    CO • D

    Sponsored 2/25/2026

  • Rep. Lawler, Michael [R-NY-17]

    NY • R

    Sponsored 2/25/2026

  • Rep. Fitzpatrick, Brian K. [R-PA-1]

    PA • R

    Sponsored 3/3/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation